Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue ...

Experiments with genetically engineered mice suggest that breaking up the protein partnership could be an effective strategy.

Q3 2025 Earnings Call Transcript November 10, 2025 FibroGen, Inc. beats earnings expectations. Reported EPS is $-1.61, ...

Tele MANAS has had an exponential reach and made mental health support accessible across the country. Here's how it works and ...

Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...

Mutations drive evolution, but they can also be risky. New research led by plant biologists at the University of California, Davis, published Nov. 10 in Proceedings of the National Academy of Sciences ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...

Discover the best home-improvement products—lab-tested, expert-approved upgrades for kitchens, baths, and beyond from Good ...

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS ...